Therapy‐related peripheral neuropathy in multiple myeloma patients

摘要: This review discusses the most common issues concerning multiple myeloma (MM)-related peripheral neuropathy (PN). is an important MM complication, observed in up to 54% of newly diagnosed patients, caused by disease itself or its treatment. Although aetiology largely unknown, a number mechanisms are suspected. It know neurological status patient, as many new antimyeloma medicines can trigger exacerbate any pre-existing neuropathy. Examples include thalidomide-induced and bortezomib-induced PN (TiPN BiTN, respectively), which key treatment options. TiPN usually sensory sensorimotor, whereas BiPN typically sensory. The chemotherapy-induced neurotoxicity well known; thalidomide seems induce through antiangiogenic properties, bortezomib connected with disrupted calcium homeostasis. incidence ranges from 25% 75%, prevalence severity appears be dose-dependent. almost 40% dose-related well. Poor (25%) reversibility prompted recommendations for dose exposure reduction, cases mostly reversible (64%). Peripheral very rare patients receiving bendamustine monotherapy. Because this favourable toxicity profile, may considered promising option combination therapies patients. Considering lack curative therapy treatment-emergent PN, prevention management strategy All should evaluated before administration neurotoxic drug, those under closely monitored neurologist.